N-Glycan Profiling
N-glycan profiling has been widely used in the identification of various diseases, including cancer, Alzheimer's, and diabetes. CD BioGlyco has rich experience in glycan profiling. Our scientists use advanced lab equipment to process samples and generate results. CD BioGlyco has confidence to be your essential research assistant at every moment.
Background
Protein post-translational modification (PTM) has been at the center of research for the worldwide scientific community. The most common PTM of protein is glycosylation, especially N-glycosylation. The synthesis of N-linked glycan starts from the endoplasmic reticulum and completes in the Golgi apparatus. N-glycosylation modification plays an important role in the process of protein folding and transportation. Its occurrence will lead to changes in stability, solubility and conformation of the protein. As glycoproteins, cytokines, monoclonal antibodies and other therapeutic proteins become popular in clinical research, there is an increasing demand for N-glycosylation analysis of these objects. However, the glycosylation analysis process is challenging due to the complexity and isomerism of glycans.
Fig 1. The biosynthesis of N-linked glycans present in the antibody (Q, Zhou.; H, Qiu. 2019)
Services
At CD BioGlyco, we perform N-Glycan profiling use the following methods.
- N-Glycan profiling by HILIC-UHPLC MS
Hydrophilic interaction chromatography is a chromatographic technique used to improve the retention of strongly polar substances that are poorly retained in reversed-phase chromatography. InstantPC (ProZyme) and RapiFluor-MS (Waters) are used to label fluorophore to the glycosamine which produced after PNGase F digestion immediately and improve the sensitivity of the entire reaction. Before fluorescent labeling, detergents, non-volatile salts or substances with free amino groups which could interfere with the experiment should be removed.

- Excellent retention performance and strong separation ability
- No need to add ion pair reagent
- Advanced technique platforms
- High sensitivity
- N-Glycan profiling by MALDI-TOF-MS
Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry is a new type of ionization biological mass spectrometry developed in recent years. It is suitable for high-throughput screening of proteins or other biological macromolecules and analyze the single nucleotide polymorphisms of oligonucleotides or genes. It is usually used as a powerful tool to analyze the molecular weight and molecular weight distribution of natural and synthetic polymers.
- Wide quality detection range and high-quality accuracy
- Fast analysis speed, strong molecular/ion peak, and intuitive information
- Strong tolerance for interference
Applications
- Proteins structure analysis
- Proteins high-throughput screening
- Therapeutic proteins development
Advantages of Us
- Highly precision equipment
- Experienced researchers
- Highly reliable results
- Stability and consistency
- Cost-effective
Case Study
Background
Aberrant glycosylation, particularly within the N-glycan landscape, is a well-established hallmark of oncogenesis and cancer progression. Mapping the precise alterations in N-glycan composition, branching patterns, and fucosylation/sialylation traits unlocks vital functional biomarkers for early diagnosis and therapeutic monitoring. However, clinical cancer tissues and biological fluids are extraordinarily complex. The co-existence of dense O-glycoproteins often interferes with N-glycan isolation, and the sheer structural diversity of carbohydrate isomers demands an analytical platform capable of complete depolymerization, ultra-high-resolution separation, and sophisticated bioinformatic deconvolution to capture subtle, cancer-specific glycan features.
Our Solution
CD BioGlyco established a specialized, multi-dimensional enzymatic N-glycan release and orthogonal MS characterization solution to perform deep-scale profiling of samples.
- Targeted N-Glycan Liberation & Partitioning: Samples were fully homogenized using an SDS-sonication matrix and reduced with 1,4-dithiothreitol (DTT) to expose buried glyco-epitopes. Following desalination, N-glycans were cleanly and selectively cleaved from the peptide backbone using peptide N-glycosidase F (PNGase F) overnight. Utilizing an advanced column chromatographic system, the liberated N-glycans were separated with high fidelity from the remaining intact O-glycoprotein fraction, ensuring an interference-free target pool.
- High-Performance Orbitrap Characterization: The isolated native N-glycan fractions were directly analyzed on a state-of-the-art MS operating in negative ion mode, which provides unmatched mass accuracy and exceptional sensitivity for complex branched and acidic/sialylated glycoforms.
- Advanced Deconvolution & Feature Mapping: The complex multi-charge raw mass spectra were processed to translate raw data into clean, single-charge neutral mass profiles.
Results
The optimized N-glycan profiling solution provided the client with an exhaustive, publication-ready data package that successfully unlocked the sample's glycan signature:
- Deconvoluted ESI-MS Fingerprinting: High-resolution mass spectra successfully generated fully deconvoluted profiles of the cancer-derived N-glycans, providing accurate mass measurements for unambiguous composition assignment.
Fig.2 Deconvoluted ESI-MS of sample N-glycans. (CD BioGlyco)
Table 1 Result of N-glycan identified. (CD BioGlyco)
| Observed (native) m/z | Composition | Proposed Structure | Abundance | |
|---|---|---|---|---|
| 2012.70 | (Hex)2 (HexNAc)2 (NeuAc)1 (Sulfate)1 + (Man)3(GlcNAc)2 | ![]() |
1.96% | |
| 2077.77 | (Hex)2 (HexNAc)2 (NeuAc)1 (Deoxyhexose)1 + (Man)3(GlcNAc)2 | ![]() |
1.21% | |
| … | … | … | … | |
- Cancer-Specific Feature Distribution: Specialized data processing resolved the exact distribution of crucial glycan features, including total fucosylation, core/antennary modifications, and sialylation levels, establishing a clear comparison matrix against baseline controls.
Table 2 N-glycan feature distribution. (CD BioGlyco)
| Glycan Feature | Cancer Sample |
|---|---|
| Oligomannose/ Paucimannose | 69.83% |
| Complex- Sialic Acid | 8.22% |
| Complex- Fucose | 8.87% |
| Complex- Sialic Acid and Fucose | 10.82% |
| Complex-Undecorated | 2.26% |

- Deep Architectural Interrogation: By implementing an in-house bioinformatic filter that excluded dominant, non-specific oligomannose compositions, our team successfully unmasked the low-abundance, complex multi-antennary and sialylated N-glycan features. This critical step allowed the client to pinpoint subtle, statistically significant alterations driving cancer-associated phenotypes.
CD BioGlyco provides a full range of glycomics analysis services, including glycan analysis, site occupation, linkage analysis, glycan sequencing, etc, as well as many customized services. We use professionalism and efficiency to complete customer’s orders and save time and funds for customers while obtaining credible results.
Customers can contact our employees directly and we will respond promptly. If you are interested in our services, please contact us for more detailed information.
Reference:
- Q, Zhou.; H, Qiu. The Mechanistic impact of N-Glycosylation on stability, pharmacokinetics, and immunogenicity of therapeutic proteins. Journal of Pharmaceutical Sciences. 2019, 108:1366-1377.
Quick Links
Resources
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform






